The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis
Journal of Cystic Fibrosis · 2023
DOI: 10.1016/j.jcf.2023.08.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2023. Verfasst von Georgene E Hergenroeder und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital; Department of Pediatrics, University of Washington. Electronic address: hergen…. Hauptthemen laut MEDLINE: Vitamin A, Cystic Fibrosis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Cystic Fibrosis Foundation, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: While elexacaftor/tezacaftor/ivacaftor (ETI) has improved the pulmonary health of many people with cystic fibrosis (PwCF), less is known about ETI effectiveness for extra-pulmonary manifestations, including fat-soluble vitamin malabsorption. This study aims to evaluate ETI's impact on vitamin A, D, E, and international normalized ratio (INR, an indirect marker for Vitamin K) serum levels. METHODS: Retrospective cohort study of PwCF ≥12 years receiving ETI. Vitamin levels up to four years preceding and up to two years following ETI initiation were collected. Pairwise comparisons of vitamin levels pre/post-ETI initiation were made using Wilcoxon signed rank and McNemar's tests. Linear mixed effect models were used to regress vitamin levels on time since starting ETI, ETI use (yes/no), the interaction between time and ETI use, and age. RESULTS: Two hundred and sixty-four participants met study inclusion, and 169 (64%) had post-ETI initiation vitamin levels. Median vitamin A levels increased from 422.0 to 471.0 mcg/L (p < 0.001), median vitamin D levels increased from 28.5 to 30.8 ng/mL (p = 0.003), and there were no significant changes in median vitamin E or INR. Vitamin A levels rose at a rate of 40.7 mcg/L/year (CI 11.3, 70.2) after ETI start. CONCLUSIONS: ETI initiation is associated with increased median vitamin A and vitamin D levels, but no change in median vitamin E or INR levels. Ongoing monitoring of vitamin levels after ETI initiation is needed to screen for potential deficiencies and toxicities, particularly in light of case reports of hypervitaminosis A following ETI initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital; Department of Pediatrics, University of Washington. Electronic address: hergenroeg@chop.edu.
- Core for Biostatistics, Epidemiology, and Analytics in Research, Seattle Children's Research Institute.
- Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital.
- Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington.
- Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital; Department of Pediatrics, University of Washington.
- Department of Pediatrics, University of Washington; Division of Gastroenterology and Hepatology, Seattle Children's Hospital.
Förderung
- NIDDK NIH HHS
- Cystic Fibrosis Foundation
- National Institutes of Health
Zitieren
APA
Hergenroeder, G. E., Faino, A., Bridges, G., Bartlett, L. E., Cogen, J. D., Green, N., McNamara, S., Nichols, D. P., & Ramos, K. J. (2023). The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2023.08.002
Vancouver
Hergenroeder GE, Faino A, Bridges G, Bartlett LE, Cogen JD, Green N, et al. The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis. Journal of Cystic Fibrosis. 2023. doi:10.1016/j.jcf.2023.08.002
BibTeX
@article{Hergenroeder2023,
author = {Hergenroeder, Georgene E and Faino, Anna and Bridges, Gracia and Bartlett, Lauren E and Cogen, Jonathan D and Green, Nicole and McNamara, Sharon and Nichols, David P and Ramos, Kathleen J},
title = {The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis},
journal = {Journal of Cystic Fibrosis},
year = {2023},
doi = {10.1016/j.jcf.2023.08.002}
}
EUVIMED